SurVaxM is an experimental vaccine for people who already have glioblastoma. It is meant to treat the tumor, not to prevent it. The vaccine teaches the immune system to recognize a protein the tumor relies on to stay alive and that healthy brain cells barely make.1PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma It is built to trigger two arms of the immune system at once. Early trials suggest it is safe and may help some people live longer, but it is still being tested and is not an approved standard treatment.
Why Survivin Makes a Good Target
The protein at the center of this vaccine is survivin. It belongs to a family of proteins that stop cells from undergoing their built-in self-destruct process.2PubMed. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma That process matters. Healthy cells that are damaged or no longer needed are programmed to die in an orderly way, which keeps tissue in balance and clears out cells with broken DNA. Cancer cells carry plenty of damage that should trigger it, so blocking it lets them survive conditions that would kill a normal cell.
Survivin is the smallest of these protective proteins, and it also helps cells split their chromosomes correctly when they divide.3PubMed Central. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination A cell rich in survivin therefore resists dying and keeps multiplying. It is found in nearly all human cancers but only barely in mature healthy adult cells.4PubMed Central. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination
Glioblastoma leans on it heavily. Malignant gliomas make survivin at high levels, while normal glial cells, the brain’s support cells, do not.5PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Brain tumor cells showed strong survivin activity while normal brain tissue showed little.6PubMed. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma Gliomas with more survivin tend to have a worse outlook.7PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Survivin also helps glioblastoma cells resist and survive temozolomide chemotherapy.8PubMed Central. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination That pattern is what makes it a reasonable target: aiming the immune system at survivin goes after something the tumor needs while largely sparing healthy brain.
How the Vaccine Sets the Immune System on the Tumor
The shot contains a short, slightly altered piece of the survivin protein linked to a carrier protein from a sea snail.9PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma The alteration is designed to provoke a stronger immune reaction than the body’s own survivin would. The carrier is there because a small piece of protein is often too small for the immune system to notice well on its own. Linking it to a larger foreign protein gives a stronger cue that something needs a response.
The vaccine is also mixed with an oily ingredient that boosts the immune response and given with sargramostim, a drug that stimulates the bone marrow’s immune cells.10PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma11PubMed Central. Brain Tumor Vaccines The oily ingredient keeps the vaccine material near the injection site, so immune cells have more time to encounter it. Sargramostim draws immune cells from the bone marrow to the area, where they help present the survivin fragment to T cells.
The result is two lines of attack. The vaccine produces survivin-specific T cells and antibodies against survivin.12PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Killer T cells directly destroy cells showing a flagged protein. Helper T cells coordinate the attack and support antibody production. Antibodies are proteins in the blood that latch onto targets and mark them.
Tumor cells chop up survivin and display fragments on their surface, where killer T cells can recognize and destroy them.13PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma In lab tests the vaccine’s peptide made both helper and killer T cells multiply, while an unrelated peptide did not.14PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma Survivin also appears on the outer surface of many cancer cells and on tiny particles tumors release, so antibodies can flag those cells for destruction.15PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma In mice, antibodies against survivin alone slowed tumor growth.16PubMed Central. Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth in vivo The vaccine targets a part of survivin shared by several versions of the protein that sit in different parts of the cell.17PubMed Central. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
It does not kill tumor cells by itself the way chemotherapy does, and it depends on the patient’s own immune system being able to respond. That is why it is given alongside surgery, radiation and chemotherapy, not instead of them.
Getting the Vaccine and Its Side Effects
In the first trial, patients got injections just under the skin every 2 weeks.18PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma Each dose contained 500 micrograms of the vaccine plus 100 micrograms of sargramostim.19PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma In trials, regular blood draws check whether the immune system is responding, and scans continue on the usual schedule to track the tumor. Doses come every few weeks, so treatment means repeated trips to a trial center rather than one appointment.
Most side effects were the mildest grade, and none of the serious ones were blamed on the vaccine.20PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma In a small early trial, six patients had redness or soreness at the injection site, three had tiredness and two had mild muscle aches.21PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Tell the care team about any injection reaction that spreads or worsens. Tiredness can be hard to separate from fatigue caused by the tumor or chemotherapy, so mention it anyway. New neurological symptoms should always be reported, since they may reflect the tumor rather than the vaccine.
What the Trial Results Show So Far
The main trial enrolled 63 newly diagnosed patients who had most or all of their visible tumor removed, then radiation and chemotherapy, followed by SurVaxM with temozolomide, the standard chemotherapy pill.22PubMed Central. Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM Half of patients went 11.4 months or longer without the tumor growing back, counted from the first vaccine dose.23PubMed Central. Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM “Progression-free” means the time before scans show the tumor growing again, so it measures control of the disease rather than survival itself. Scan changes after radiation can sometimes look like growth when they are treatment effects, which makes this measure harder to read. Half lived 25.9 months or longer from that first dose.24PubMed Central. Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM That midpoint is called median survival: half of patients lived longer than it and half less.
The benefit appeared both in patients whose tumors respond well to temozolomide, called MGMT methylated on reports, and in those whose tumors do not.25PubMed Central. Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme Every patient got the vaccine, though, so there was no untreated group to compare against.
That limits what the numbers can say. The clock started after chemoradiation, so time from diagnosis is longer. Patients in this trial also had extensive surgery, which already favors longer survival, and trial patients are often healthier than average. A larger randomized trial is needed to confirm that the vaccine adds survival.
Longer survivors had tumors that already showed signs of active immune signaling before treatment.26PubMed Central. Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM They also had more B cells, the immune cells that make antibodies, inside their tumors.27PubMed Central. Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM How well the vaccine works may therefore depend on how active the immune system already is in a person’s tumor. This was an observation, not a proven test of who will benefit. Patients whose disease stayed controlled longer often saw fewer survivin-carrying tumor particles in their blood after vaccination.28PubMed Central. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination
In an earlier trial of nine people whose glioma had come back, seven lived more than 12 months.29PubMed Central. Brain Tumor Vaccines Six of eight patients tested made both antibodies and T cells against survivin.30PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Why Glioblastoma Is Hard for Any Vaccine
Immune treatments that transformed other cancers have not done the same for glioblastoma.31PubMed Central. Tumor microenvironment in glioblastoma: Current and emerging concepts The tumor varies from cell to cell, provokes little immune reaction, suppresses immune cells around it, and sits behind the blood-brain barrier that limits immune cells entering.32PubMed Central. Tumor microenvironment in glioblastoma: Current and emerging concepts
That barrier is a tightly sealed lining of blood vessels that protects the brain by controlling what moves from blood into brain tissue. The same protection limits how easily immune cells and many drugs reach a tumor. Vaccine-trained cells must cross it in useful numbers, and that is not guaranteed.
Inside the tumor, other immune cells crowd in, switch off killer T cells and help the tumor grow.33PubMed Central. Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers Glioblastoma shows few warning signals to the immune system and has ways of dodging attack.34PubMed Central. Heterogeneity and individualized treatment of microenvironment in glioblastoma A vaccine tries to overcome this by teaching the immune system to look for a specific marker in advance. Even so, well-trained T cells may arrive and be shut down. This fits the trial findings: patients whose tumors already had active immune signaling did better.
Aiming at one protein has limits too. Some tumor cells may make less survivin and slip past, and variety among tumor cells makes any single target incomplete.
Who Can Get SurVaxM and Where Research Is Heading
Access is through clinical trials. Trials have required tumors that test positive for survivin.35PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma They have also required certain tissue types on an HLA blood test, such as HLA-A*02 or A*03, and in one trial A*11 or A*24.36PubMed Central. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma37PubMed Central. Brain Tumor Vaccines The immune system displays protein fragments using these HLA markers, and the vaccine’s fragment fits certain types. Without a suitable type, the fragment may not be shown to T cells and the patient may not qualify. Survivin testing is done on tumor tissue from surgery, since the vaccine only makes sense if the tumor makes the protein.
A trial is testing SurVaxM with pembrolizumab, a drug that releases a brake on T cells, for glioblastoma at first recurrence.38PubMed Central. CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE It includes a small group whose tumors already failed similar brake-releasing drugs.39PubMed Central. CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE A study in children with relapsed brain tumors and newly diagnosed DIPG is recruiting in the US and Canada.40Nature Biopharma Dealmakers. Developing a new cancer immunotherapy, SurVaxM from bench to bedside The vaccine is being tested in neuroendocrine tumors and multiple myeloma as well.41Roswell Park Comprehensive Cancer Center. MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors Other survivin vaccines built from overlapping pieces of the whole protein are in early testing for advanced solid tumors.42PubMed Central. Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study
To explore a trial, start by asking the neuro-oncologist whether the tumor tissue has been tested for survivin, and about HLA typing, a simple blood test. Then search ClinicalTrials.gov for SurVaxM and check which stage of disease each trial accepts. Timing matters, since some trials enroll right after chemoradiation. Useful questions for the trial team: how often visits are and where they happen, whether standard treatment continues alongside the vaccine, what costs are covered, and what happens if the tumor grows during the trial. Being turned away from one trial does not rule out others that accept different patients.